top of page

Understanding Messenger RNA and Other SARS-CoV-2 Vaccines

Michael E. Pichichero, MD


In mid-November, Pfizer/BioNTech were the first with surprising positive protection interim data for their coronavirus vaccine, BNT162b2. A week later, Moderna released interim efficacy results showing its coronavirus vaccine, mRNA-1273, also protected patients from developing SARS-CoV-2 infections. Both studies included mostly healthy adults. A diverse ethnic and racial vaccinated population was included. A reasonable number of persons aged over 65 years, and persons with stable compromising medical conditions were included. Adolescents aged 16 years and over were included. Younger adolescents have been vaccinated or such studies are in the planning or early implementation stage as 2020 came to a close.


Read more here : https://www.medscape.com/viewarticle/942654?src=mkm_covid_update_201215_MSCPEDIT&uac=218819SG&impID=2739343&faf=1

2 views0 comments

Recent Posts

See All

Comentarios


bottom of page